Which has preferable earnings and valuation, KYTX or DMRA?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is KYTX or DMRA more profitable?

Kyverna Therapeutics' return on equity of -81.88% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Does the media prefer MRVI or KYTX?

In the previous week, Maravai LifeSciences had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Maravai LifeSciences and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.88 beat Maravai LifeSciences' score of 0.48 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, KYTX or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is KYTX or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Bicara Therapeutics N/A -35.89% -33.78%

Does the media prefer KYTX or BCAX?

In the previous week, Bicara Therapeutics had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Bicara Therapeutics and 1 mentions for Kyverna Therapeutics. Bicara Therapeutics' average media sentiment score of 1.13 beat Kyverna Therapeutics' score of 0.88 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KYTX or SNDX?

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Syndax Pharmaceuticals and 1 mentions for Kyverna Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat Kyverna Therapeutics' score of 0.88 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, KYTX or AAPG?

Kyverna Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Ascentage Pharma Group International $82.10M 19.13 -$177.71M N/A N/A

Is KYTX or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Ascentage Pharma Group International N/A N/A N/A

Kyverna Therapeutics (KYTX) Competitors

$7.68 +0.17 (+2.26%)

As of 11:22 AM Eastern

Compare

KYTX vs. DMRA, MRVI, BCAX, SNDX, and AAPG

Should you buy Kyverna Therapeutics stock or one of its competitors? MarketBeat compares Kyverna Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyverna Therapeutics include Damora Therapeutics, Inc. Common Stock (DMRA), Maravai LifeSciences (MRVI), Bicara Therapeutics (BCAX), Syndax Pharmaceuticals (SNDX), and Ascentage Pharma Group International (AAPG).

How does Kyverna Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Kyverna Therapeutics (NASDAQ:KYTX) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Damora Therapeutics, Inc. Common Stock had 7 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 8 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.88 beat Damora Therapeutics, Inc. Common Stock's score of -0.16 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Damora Therapeutics, Inc. Common Stock	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kyverna Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 290.63%. Damora Therapeutics, Inc. Common Stock has a consensus price target of $44.00, suggesting a potential upside of 49.30%. Given Kyverna Therapeutics' higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Kyverna Therapeutics' return on equity of -81.88% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Kyverna Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Summary

Kyverna Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Maravai LifeSciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

In the previous week, Maravai LifeSciences had 3 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for Maravai LifeSciences and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.88 beat Maravai LifeSciences' score of 0.48 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences presently has a consensus target price of $5.50, indicating a potential downside of 14.00%. Kyverna Therapeutics has a consensus target price of $30.00, indicating a potential upside of 290.63%. Given Kyverna Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Maravai LifeSciences has higher revenue and earnings than Kyverna Therapeutics. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.89	-$130.77M	-$0.71	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

Kyverna Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Summary

Kyverna Therapeutics beats Maravai LifeSciences on 8 of the 15 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Bicara Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kyverna Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 290.63%. Bicara Therapeutics has a consensus target price of $30.27, indicating a potential upside of 14.65%. Given Kyverna Therapeutics' higher possible upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Kyverna Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Bicara Therapeutics' return on equity of -35.89% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Bicara Therapeutics	N/A	-35.89%	-33.78%

In the previous week, Bicara Therapeutics had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Bicara Therapeutics and 1 mentions for Kyverna Therapeutics. Bicara Therapeutics' average media sentiment score of 1.13 beat Kyverna Therapeutics' score of 0.88 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bicara Therapeutics beats Kyverna Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Kyverna Therapeutics (NASDAQ:KYTX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Syndax Pharmaceuticals and 1 mentions for Kyverna Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.03 beat Kyverna Therapeutics' score of 0.88 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyverna Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 290.63%. Syndax Pharmaceuticals has a consensus price target of $42.55, indicating a potential upside of 119.08%. Given Kyverna Therapeutics' higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Kyverna Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Syndax Pharmaceuticals	$172.35M	9.98	-$285.42M	-$2.79	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kyverna Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Kyverna Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -111.88%. Kyverna Therapeutics' return on equity of -81.88% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Summary

Kyverna Therapeutics and Syndax Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Kyverna Therapeutics compare to Ascentage Pharma Group International?

Kyverna Therapeutics (NASDAQ:KYTX) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Ascentage Pharma Group International's return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Ascentage Pharma Group International	N/A	N/A	N/A

Kyverna Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Ascentage Pharma Group International	$82.10M	19.13	-$177.71M	N/A	N/A

Kyverna Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Kyverna Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 290.63%. Ascentage Pharma Group International has a consensus price target of $46.43, suggesting a potential upside of 176.03%. Given Kyverna Therapeutics' higher possible upside, research analysts clearly believe Kyverna Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

In the previous week, Ascentage Pharma Group International had 2 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 0.88 beat Ascentage Pharma Group International's score of 0.54 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats Kyverna Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Kyverna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYTX vs. The Competition

Export

Metric	Kyverna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$466.26M	$3.53B	$6.80B	$12.89B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-2.34	7.33	279.90	25.40
Price / Sales	N/A	1,274.10	648.58	114.39
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.99	17.12	11.10	6.30
Net Income	-$161.31M	-$12.52M	$3.48B	$347.60M
7 Day Performance	2.54%	1.54%	1.93%	2.53%
1 Month Performance	-13.61%	-6.32%	-3.29%	-2.57%
1 Year Performance	127.89%	49.25%	62.38%	20.26%

Kyverna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYTX Kyverna Therapeutics	2.3634 of 5 stars	$7.68 +2.3%	$30.00 +290.6%	+118.3%	$466.26M	N/A	N/A	96	Upcoming Earnings
DMRA Damora Therapeutics, Inc. Common Stock	2.1009 of 5 stars	$29.42 -0.1%	$43.38 +47.4%	+785.6%	$1.81B	N/A	N/A	40	Upcoming Earnings
MRVI Maravai LifeSciences	1.6899 of 5 stars	$6.86 +2.5%	$5.50 -19.8%	+189.2%	$1.77B	$204.73M	N/A	610	Upcoming Earnings Analyst Downgrade
BCAX Bicara Therapeutics	2.1271 of 5 stars	$26.88 -3.3%	$30.27 +12.6%	+144.4%	$1.77B	N/A	N/A	32	Positive News Upcoming Earnings
SNDX Syndax Pharmaceuticals	2.8147 of 5 stars	$19.63 -4.3%	$42.55 +116.7%	+92.8%	$1.74B	$172.35M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYTX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. DMRA, MRVI, BCAX, SNDX, and AAPG

How does Kyverna Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Kyverna Therapeutics compare to Maravai LifeSciences?

Summary

How does Kyverna Therapeutics compare to Bicara Therapeutics?

Summary

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Kyverna Therapeutics compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyverna Therapeutics (KYTX) Competitors

KYTX vs. DMRA, MRVI, BCAX, SNDX, and AAPG

How does Kyverna Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Does the media favor KYTX or DMRA?

Which has preferable earnings and valuation, KYTX or DMRA?

Do institutionals & insiders have more ownership in KYTX or DMRA?

Do analysts recommend KYTX or DMRA?

Is KYTX or DMRA more profitable?

Which has more risk & volatility, KYTX or DMRA?

Summary

How does Kyverna Therapeutics compare to Maravai LifeSciences?

Do insiders and institutionals believe in MRVI or KYTX?

Which has more risk & volatility, MRVI or KYTX?

Does the media prefer MRVI or KYTX?

Do analysts rate MRVI or KYTX?

Which has better earnings & valuation, MRVI or KYTX?

Is MRVI or KYTX more profitable?

Summary

How does Kyverna Therapeutics compare to Bicara Therapeutics?

Do institutionals and insiders believe in KYTX or BCAX?

Do analysts rate KYTX or BCAX?

Which has preferable earnings and valuation, KYTX or BCAX?

Which has more volatility and risk, KYTX or BCAX?

Is KYTX or BCAX more profitable?

Does the media prefer KYTX or BCAX?

Summary

How does Kyverna Therapeutics compare to Syndax Pharmaceuticals?

Does the media favor KYTX or SNDX?

Do analysts recommend KYTX or SNDX?

Which has higher valuation and earnings, KYTX or SNDX?

Do institutionals and insiders hold more shares of KYTX or SNDX?

Which has more risk and volatility, KYTX or SNDX?

Is KYTX or SNDX more profitable?

Summary

How does Kyverna Therapeutics compare to Ascentage Pharma Group International?

Is KYTX or AAPG more profitable?

Which has stronger valuation and earnings, KYTX or AAPG?

Which has more risk and volatility, KYTX or AAPG?

Do analysts rate KYTX or AAPG?

Does the media favor KYTX or AAPG?

Do insiders & institutionals believe in KYTX or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYTX vs. The Competition

Kyverna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools